Colon Cancer Survivors - Medications and Risk of RecurrenceBackgroundColorectal cancer was diagnosed in over 100,000 Americans in 2001. To combat this disease, new avenues to decrease the risk of colorectal cancer, such as chemoprevention, are being explored by CRN researchers at two sites. Non-steroidal anti-inflammatory drugs (NSAIDs) and hormone replacement therapy (HRT) have been shown to decrease incident colon cancer. Little is known, however, about their effect on persons with a history of colon cancer, which, fortunately, is a continually expanding population as survival has been significantly improving over the last twenty years. Study AimsThe specific aims are:
MethodsThe research team has established a cohort of over 1,000 colorectal cancer patients treated with curative intent, and created a comprehensive longitudinal database, including data on the ascertainment of subsequent adenomatous polyps, colorectal cancer and survival. Cohort subjects will be followed for at least five years for new evidence of disease, recurrence, and survival outcome. Using automated pharmacy data, the timing of use and exposure to NSAIDs and HRT will be analyzed among cancer survivors. SignificanceCancers of the colon and rectum are the fourth most commonly diagnosed cancers and rank second among cancer deaths in the United States. Still, over 50 percent of colon cancer patients survive for ten years or longer, necessitating a better understanding of aspects that increase or decrease the likelihood of recurrence. Project StatusThis study was funded as an investigator-initiated R01 (Research Project), and is closely affiliated with the CRN. Christine Johnson, PhD, from Henry Ford Health System, is the Principal Investigator. Data collection is ongoing. |
Care & Treatment Research:
|
Home |
About CRN |
Collaborating with CRN |
Project Portfolio
Scientific & Data Resources | Dissemination | Related Links |
Maintained by the
Applied Research Program,
Division of Cancer Control & Population Sciences. Accessibility Feedback | Privacy Policy |